Han Wha Pharma(Kim, Kyoungrak / President) revealed on June 19 that it has won the Korea Food and Drug Administration’s approval to conduct a second-stage clinical trial for its new herbal medicinal products against diabetic endothelial dysfunction. The drug, “YJP-14” is made from natural substances and has been proven safe for long term use based on animal tests. Its effects increase nitric oxide